394
Views
4
CrossRef citations to date
0
Altmetric
Reviews

Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies

&
Pages 8-31 | Received 10 Jul 2020, Accepted 16 Sep 2020, Published online: 02 Nov 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Daria Gaut, Caspian Oliai, Jonathan Boiarsky, Shiliang Zhang, Amandeep Salhotra, Tali Azenkot, Vanessa E. Kennedy, Vishesh Khanna, Karla Olmedo Gutierrez, Navika Shukla, Benjamin Moskoff, Gabriel Park, Michelle Afkhami, Anand Patel, Deepa Jeyakumar, Gabriel Mannis, Aaron C. Logan, Brian A. Jonas & Gary Schiller. (2023) Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leukemia & Lymphoma 0:0, pages 1-9.
Read now

Articles from other publishers (3)

Ing S. Tiong & Sun Loo. (2023) Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. International Journal of Molecular Sciences 24:5, pages 4790.
Crossref
Tali Azenkot & Brian A. Jonas. (2022) Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia. Cancers 14:15, pages 3634.
Crossref
Takaaki Konuma, Tadakazu Kondo, Masayoshi Masuko, Hiroaki Shimizu, Souichi Shiratori, Takahiro Fukuda, Jun Kato, Masashi Sawa, Yukiyasu Ozawa, Shuichi Ota, Naoyuki Uchida, Yoshinobu Kanda, Shinichi Kako, Shin Fujisawa, Kentaro Fukushima, Tatsuo Ichinohe, Yoshiko Atsuta & Masamitsu Yanada. (2021) Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone Marrow Transplantation 56:11, pages 2779-2787.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.